When was XORTX Pharma founded?

XORTX Pharma was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is XORTX Pharma located?

XORTX Pharma is headquartered in Calgary, Canada.

How many employees does XORTX Pharma have?

As of May 31, 2026, the latest employee count at XORTX Pharma is 6.

Is XORTX Pharma a funded company?

XORTX Pharma is a funded company, having raised a total of $450K across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 15, 2012.

When was the latest funding round of XORTX Pharma?

XORTX Pharma's latest funding was a $***** Post IPO round on Aug 08, 2025, with participation from 0 investor.

Where does XORTX Pharma rank among its competitors?

XORTX Pharma ranks 118th amongst 514 active competitors, of which 168 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was XORTX Pharma, which secured $83.3K in Aug, 2025.

Who are the top competitors of XORTX Pharma?

XORTX Pharma's top competitors include BridgeBio, Alnylam and Alexion. Among them, XORTX Pharma secured the most recent funding round in August, 2025.

XORTX Pharma - 2026 Company Profile, Funding & Competitors

Company Details

XORTX is a therapeutics company spun out from the University of Florida, with a focus on orphan disease markets such as rare kidney diseases caused by improper uric acid metabolism. Its drug pipeline includes therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Phase 1), and Diabetic Nephropathy (DN), which target the renin-angiotensin-aldosterone system (RAAS).

Website: www.xortx.com/
Social
Email ID: *****@xortx.com

Key Metrics

Founded Year

2012

Location

Calgary, Canada

Stage

Public

Total Funding

$450K in 8 rounds

Latest Funding Round

Post IPO, Aug 08, 2025, $*****

Ranked

118^th among 514 active competitors

Employee Count

6 as on May 31, 2026

Similar Companies

BridgeBio & 609 more

Exit Details

Public

View XORTX Pharma's full profile

XORTX Pharma got listed on Jan 11, 2018.

Click here to take a look at XORTX Pharma's IPO in detail

XORTX Pharma has raised a total funding of $450K over 8 rounds. Its first funding round was on Sep 15, 2012.

Here is the list of recent funding rounds of XORTX Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 08, 2025	6965553	Post IPO	4784897	7392460	9096766	3658833
Jun 26, 2025	4363299	Post IPO	9803883	4790778	1932347	7232041
Feb 15, 2024	8531977	Post IPO	5400044	7212452	1462447	6460972

Access funding benchmarks and valuations. Sign up today!

View details of XORTX Pharma's funding rounds and investors

XORTX Pharma's employee count trend

XORTX Pharma has 6 employees as of May 26. Here is XORTX Pharma's employee count trend over the years:

Uncover XORTX Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of XORTX Pharma include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of XORTX Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
7th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Flagship Pioneering, Arch Venture Partners ... & 6 others	70/100
8th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
9th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
10th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Third Rock Ventures & 9 others	70/100
118th	XORTX Pharma 2012, Calgary (Canada), Public	Therapeutics for the treatment kidney diseases caused by improper uric acid metabolism.	$450K	-	50/100